Goldman Sachs resumed coverage of CG Oncology (CGON) with a Buy rating and $40 price target The firm believes the clinical profile of cretostimogene is competitive with TAR-200.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- CG Oncology price target raised to $56 from $52 at Morgan Stanley
- CG Oncology Holds 2025 Annual Stockholders Meeting
- Promising Market Position and Investment Opportunity: CG Oncology’s Creto in NMIBC Treatment
- CG Oncology Advances Bladder Cancer Therapies in Q1 2025
- Promising Outlook for CG Oncology: Strong Financial Health and Positive Trial Results for Cretostimogene